Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Regeneron Pharmaceuticals Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax increased by 1032.0% to $28.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 59.9%, from $17.70M to $28.30M. Over 5 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax shows an upward trend with a 65.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Higher unrealized losses often signal rising interest rates or credit deterioration in the investment portfolio.
Detailed definition
This metric tracks the total gross unrealized losses on debt securities classified as available-for-sale. It represents...
Peer comparison
Unrealized losses are a key focus for investors during periods of rising interest rates, as they impact the bank's book value.
other_available_for_sale_debt_securities_accumulated_gro_6005e2Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.70M | $7.00M | $42.30M | $216.20M | $282.40M | $346.80M | $302.80M | $240.10M | $250.90M | $224.00M | $115.80M | $104.70M | $91.70M | $26.00M | $39.00M | $17.70M | $10.20M | $6.00M | $2.50M | $28.30M |
| QoQ Change | — | +89.2% | +504.3% | +411.1% | +30.6% | +22.8% | -12.7% | -20.7% | +4.5% | -10.7% | -48.3% | -9.6% | -12.4% | -71.6% | +50.0% | -54.6% | -42.4% | -41.2% | -58.3% | >999% |
| YoY Change | — | — | — | — | >999% | >999% | +615.8% | +11.1% | -11.2% | -35.4% | -61.8% | -56.4% | -63.5% | -88.4% | -66.3% | -83.1% | -88.9% | -76.9% | -93.6% | +59.9% |
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Regeneron Pharmaceuticals (REGN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $28.30M in Q1 2026.
- How has Regeneron Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Regeneron Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 59.9% year-over-year, from $17.70M to $28.30M.
- What is the long-term trend for Regeneron Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a 65.7% compound annual growth rate (CAGR), from $200.00K to $2.50M.
- What does debt securities, available-for-sale, accumulated gross unrealized loss, before tax mean?
- The total amount of unrealized losses on debt securities that are held for potential sale.